Results obtained using cisplatin/etoposide as first-line therapy in advanced or metastatic high-grade neuroendocrine carcinoma
| Objective responses | LCNEC | SCLC |
| Complete response | 2 (7.1%) | 1 (2.3%) |
| Partial response | 16 (57.1%) | 25 (56.8%) |
| Stable disease | 5 (17.9%) | 13 (29.5%) |
| Progressive disease | 5 (17.9%) | 5 (11.4%) |
| Response rate | 18 (64.2%) | 26 (59.1%) |
| Disease control | 23 (82.1%) | 39 (88.6%) |
| Survival data | ||
| PFS months | 7.4 (1–92.4) | 6.1 (1–130.2) |
| 6-month PFS | 53.6% | 52.3% |
| 12-months PFS | 25% | 15.9% |
| OS months | 10.4 (1–84.4) | 10.9 (1.6–130.2) |
| 6-month OS | 64.3% | 75% |
| 12-months OS | 35.7% | 38.6% |
Data are presented as n (%), median (range) or %. LCNEC: large cell neuroendocrine carcinoma; SCLC: small cell lung cancer; PFS: progression-free survival; OS: overall survival.